Sanofi-Aventis
WHO delists Sanofi-Aventis combo vaccine
August 10, 2010Manufacturing and Production, Sales and Marketing Sanofi-Aventis, WHO, vaccines
The World Health Organization has dropped a combination vaccine made by Sanofi-Aventis’ subsidiary Shantha Biologics from its list of prequalified …
Sanofi appoints Dr Ian Weatherhead UK coms director
August 4, 2010Medical Communications, Research and Development, Sales and Marketing Sanofi-Aventis, UK, appointment, research and development, sales and marketing
Sanofi-Aventis UK has appointed Dr Ian Weatherhead as its director of communications. Ian will join the Guildford-based company in October, …
Sanofi’s blockbusters take a hit
July 29, 2010Sales and Marketing 2010 financials, Genzyme, Q2, Sanofi-Aventis
Generic pressures, European pricing pressures and the impact of the US health reforms combined to dent Sanofi-Aventis’s growth in the …
Genzyme ponders Sanofi offer
July 27, 2010Research and Development, Sales and Marketing Genzyme, Sanofi-Aventis
Sanofi-Aventis is understood to have approached the board of Genzyme with a takeover bid for the company. News agency Reuters …
Generic Lovenox to dent Sanofi’s earnings
July 26, 2010Sales and Marketing Lovenox, Sandoz, Sanofi-Aventis, generics
A generic version of Sanofi-Aventis’ blockbuster anti-blood clot treatment Lovenox has just gained approval in the US, signaling a rapid …
US approval for Sanofi’s Jevtana
July 19, 2010Sales and Marketing Jevtana, Sanofi-Aventis, chemotherapy, prostate cancer
US regulators have approved Sanofi-Aventis’ chemotherapy agent Jevtana in combination with the steroid prednisone to treat men with prostate cancer. …
Pharma manufacturing news in brief
July 6, 2010Manufacturing and Production BMS, Borregaard Synthesis, Colorcon, JHP Pharma, Saltigo, Sanofi-Aventis, Synthetech, Viropharma, univar
New capital investments from Sanofi-Aventis, Bristol-Myers Squibb, Viropharma and Colorcon head up this round-up of developments in the pharmaceutical manufacturing …
Sanofi licences novel oral anti-diabetic treatment
June 25, 2010Research and Development, Sales and Marketing Metabolex, Sanofi-Aventis, diabetes
Sanofi-Aventis has signed an exclusive worldwide licensing agreement with US-based diabetes specialist Metabolex for a novel oral anti-diabetic treatment. MBX-2982 …
Sanofi signs microRNA therapy deal
June 23, 2010Research and Development RNA, Regulus, Sanofi-Aventis
Sanofi-Aventis has entered into a global strategic alliance with US-based therapeutics firm Regulus to develop and commercialise microRNA therapeutics. Regulus …
Sanofi signs biomedical collaboration with MIT
May 27, 2010Research and Development MIT, Sanofi-Aventis, academia, biomedical
Sanofi-Aventis has formed a strategic alliance with the Centre for Biodmedical Innovation at the Massachusetts Institute of Technology. The alliance, …
Sanofi signs Indian pain drug development deal
May 5, 2010Research and Development Glenmark, Sanofi-Aventis, chronic pain, pain therapeutics
Sanofi-Aventis has signed an agreement with Indian firm Glenmark Pharmaceuticals to develop novel agents for the treatment of chronic pain. …
Sanofi’s chief strategic officer to step down
May 4, 2010Sales and Marketing Sanofi-Aventis, appointment, sales and marketing
Laurence Debroux, chief strategic officer at Sanofi-Aventis, is to leave the company at the end of June. The company said …
NICE changes its mind on Multaq
March 30, 2010Sales and Marketing Multaq, NICE, Sanofi-Aventis
NICE has given preliminary approval of Sanofi-Aventis’ Multaq for the management of patients with atrial fibrillation. The decision reverses an …
WHO suspends use of Sanofi-Aventis vaccine
March 18, 2010Manufacturing and Production Sanofi-Aventis, Shantha Biotechnics, Vaccine
The World Health Organization has temporarily stopped procurement and use of a combination vaccine supplied by Sanofi-Aventis subsidiary Shantha Biotechnics …
Sanofi’s breast cancer candidate tipped for future success
February 25, 2010Research and Development, Sales and Marketing BSI-201, Sanofi-Aventis, breast cancer
A Sanofi-Aventis drug currently in phase III has been predicted as a future blockbuster in breast cancer treatment. Sanofi’s BSI-201 …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
